Pexiganan acetate
Based on 1 publication(s) in Google Scholar
Pexiganan (MSI 78) acetate is an orally active antimicrobial peptide with broad-spectrum bactericidal. Pexiganan TFA disrupts bacterial cell membranes, induces peptidoglycan damage and cell lysis. Pexiganan acetate can be used for the research of bacterial infection.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.31%
- CAS 番号: 172820-23-4
- 分子式: C122H210N32O22.xC2H4O2
- 分子量:2477.17 (free base)
-
保管条件:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Pexiganan acetate
More
生物活性
製品説明
体外実験
Pexiganan (1-256 µg/mL; 24 h) acetate exhibits comparable bactericidal activity against planktonic Staphylococcus aureus Z25.2, Pseudomonas aeruginosa Z25.1, and their dual-species cultures[1].
Pexiganan (1-256 µg/mL; 24 h) acetate is more effective at inhibiting and eradicating Staphylococcus aureus Z25.2 biofilms than Pseudomonas aeruginosa Z25.1 or dual-species biofilms[1].
Pexiganan (7-35 μM) acetate binds to purified bovine type I collagen with a dissociation constant of 34.01 μM[3].
Pexiganan (5-80 μg/mL; overnight) acetate inhibits the growth of Pseudomonas aeruginosa and Staphylococcus aureus[3].
Pexiganan (40 μg/mL; 0-60 min) acetate rapidly reduces viable counts of Pseudomonas aeruginosa (ATCC27853) and Staphylococcus aureus (ATCC29213) over 60 min, with complete elimination of P. aeruginosa by 60 min[3].
Pexiganan (10-50 μg/mL) acetate exhibits no cytotoxicity toward rat fibroblast cells in in vitro MTT assays[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
Pexiganan (1 mg/kg; i.p.; single dose) acetate reduces lethality, and intra-abdominal bacterial counts in E. coli-induced septic shock in male Wistar rats[4].
Pexiganan (1 mg/kg; i.p.; single dose) acetate reduces lethality, and intra-abdominal bacterial counts in in cecal ligation and puncture-induced septic shock in male Wistar rats[4].
Pexiganan (1 mg/kg; i.p.; single dose) acetate is well-tolerated with no detectable adverse effects or physiological changes in healthy male Wistar rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (adult male, 200-300 g, E. coli O111:B4 LPS (HY-D1056A1)-induced septic shock)[4]
-
Dosage:1 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced plasma endotoxin levels to ≤0.015 EU/mL.
Reduced plasma TNF-α levels to 0.26 ng/mL.
-
Animal Model:Wistar rats (adult male, 200-300 g, E. coli-induced septic shock)[4]
-
Dosage:1 mg/kg
-
Administration:i.p.; single dose
-
Result:Resulted in 32.3% lethality, 5/15 positive blood cultures, and intra-abdominal bacterial counts of 6.0 × 103 CFU/mL.
-
Animal Model:Wistar rats (adult male, 200-300 g, cecal ligation and puncture-induced septic shock)[4]
-
Dosage:1 mg/kg
-
Administration:i.p.; single dose
-
Result:When administered immediately after surgery, resulted in 32.3% lethality, 5/15 positive blood cultures, and intra-abdominal bacterial counts of 6.9 × 103 CFU/mL.
When administered immediately after surgery, produced significant reductions in plasma endotoxin and TNF-α levels compared to control and β-lactam-treated groups.
When administered 360 minutes after surgery, resulted in 40.0% lethality, 6/15 positive blood cultures, and intra-abdominal bacterial counts of 6.0 × 104 CFU/mL.
When administered 360 minutes after surgery, produced significant reductions in plasma endotoxin and TNF-α levels compared to control and β-lactam-treated groups.
-
Animal Model:Wistar rats (adult male, 200-300 g)[4]
-
Dosage:1 mg/kg
-
Administration:i.p.; single dose
-
Result:Showed no drug-related adverse effects.
Caused no changes in measured physiological parameters including leukocyte count, serum creatinine, rectal temperature, pulse, blood pressure, breathing rate, and oxygenation.
化学情報
-
CAS 番号 172820-23-4
-
性状 Solid
-
分子量 2477.17 (free base)
-
分子式 C122H210N32O22.xC2H4O2
-
Color White to off-white
-
別名
MSI 78
-
配列
Gly-Ile-Gly-Lys-Phe-Leu-Lys-Lys-Ala-Lys-Lys-Phe-Gly-Lys-Ala-Phe-Val-Lys-Ile-Leu-Lys-Lys-NH2
-
シーケンスの短縮
GIGKFLKKAKKFGKAFVKILKK-NH2
-
Structure Classification
-
Initial Source
the skin of the African clawed frog
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
純度とドキュメンテーション
-
データシート (283 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Gomes D, et al. Pexiganan in Combination with Nisin to Control Polymicrobial Diabetic Foot Infections. Antibiotics (Basel). 2020;9(3):128. Published 2020 Mar 20. [Content Brief]
[2]. Ghazvini K, et al. Sustain-release lipid-liquid crystal formulations of pexiganan against Helicobacter pylori infection: in vitro evaluation in C57BL/6 mice. BMC Pharmacol Toxicol. 2024;25(1):9. Published 2024 Jan 11. [Content Brief]
[3]. Gopinath D, et al. Pexiganan-incorporated collagen matrices for infected wound-healing processes in rat. J Biomed Mater Res A. 2005;73(3):320-331. [Content Brief]
[4]. Giacometti A, et al. Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock. Peptides. 2005;26(2):207-216. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Pexiganan acetate 関連分類
HY-105088A 関連分類
Powered by Bioz
Keywords